1. Home
  2. LPTX vs KNDI Comparison

LPTX vs KNDI Comparison

Compare LPTX & KNDI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LPTX
  • KNDI
  • Stock Information
  • Founded
  • LPTX 2011
  • KNDI 2002
  • Country
  • LPTX United States
  • KNDI China
  • Employees
  • LPTX N/A
  • KNDI N/A
  • Industry
  • LPTX Biotechnology: Biological Products (No Diagnostic Substances)
  • KNDI Auto Manufacturing
  • Sector
  • LPTX Health Care
  • KNDI Consumer Discretionary
  • Exchange
  • LPTX Nasdaq
  • KNDI Nasdaq
  • Market Cap
  • LPTX 119.6M
  • KNDI 96.3M
  • IPO Year
  • LPTX N/A
  • KNDI N/A
  • Fundamental
  • Price
  • LPTX $0.33
  • KNDI $1.20
  • Analyst Decision
  • LPTX Hold
  • KNDI
  • Analyst Count
  • LPTX 1
  • KNDI 0
  • Target Price
  • LPTX N/A
  • KNDI N/A
  • AVG Volume (30 Days)
  • LPTX 3.3M
  • KNDI 109.2K
  • Earning Date
  • LPTX 08-11-2025
  • KNDI 08-15-2025
  • Dividend Yield
  • LPTX N/A
  • KNDI N/A
  • EPS Growth
  • LPTX N/A
  • KNDI N/A
  • EPS
  • LPTX N/A
  • KNDI N/A
  • Revenue
  • LPTX N/A
  • KNDI $127,569,613.00
  • Revenue This Year
  • LPTX N/A
  • KNDI N/A
  • Revenue Next Year
  • LPTX N/A
  • KNDI N/A
  • P/E Ratio
  • LPTX N/A
  • KNDI N/A
  • Revenue Growth
  • LPTX N/A
  • KNDI 3.21
  • 52 Week Low
  • LPTX $0.22
  • KNDI $0.89
  • 52 Week High
  • LPTX $4.79
  • KNDI $2.07
  • Technical
  • Relative Strength Index (RSI)
  • LPTX 48.69
  • KNDI 52.54
  • Support Level
  • LPTX $0.28
  • KNDI $1.09
  • Resistance Level
  • LPTX $0.36
  • KNDI $1.17
  • Average True Range (ATR)
  • LPTX 0.04
  • KNDI 0.07
  • MACD
  • LPTX 0.01
  • KNDI 0.01
  • Stochastic Oscillator
  • LPTX 39.43
  • KNDI 61.23

About LPTX Leap Therapeutics Inc.

Leap Therapeutics Inc is in developing targeted antibody therapies for cancer treatment, focusing on inhibiting tumor-promoting pathways, targeting cancer-specific cell surface molecules, and activating the immune system against cancer cells. The company's lead program, DKN-01, targets Dickkopf-related protein 1 (DKK1) and is in clinical trials for esophagogastric, gynecologic, and colorectal cancers. Their second program, FL-301, targets Claudin18.2-expressing cells. Additionally, the company has two preclinical antibody programs, FL-302 and FL-501, aimed at developing transformative cancer treatments. Operating as a single segment, the company's sole focus is on developing innovative drugs to address unmet needs in cancer therapy. .

About KNDI Kandi Technologies Group Inc

Kandi Technologies Group Inc is engaged in developing, manufacturing, and commercializing fully electric vehicle products and related technologies. Its products mainly consist of EV parts, EV products, and off-road vehicles, including All-Terrain Vehicles (ATVs), UTVs, go-karts, electric scooters, electric self-balancing scooters, and associated parts, and Lithium-ion cells, etc. The company generates maximum revenue from the sale of Off-road vehicles and associated parts. Geographically, it derives maximum revenue from the United States and other countries, followed by China.

Share on Social Networks: